Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 10Terminated 2No longer available 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Trophoblastic Tumor, Placental Site 1Gestational Trophoblastic Disease 1Choriocarcinoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × carotuximab × Clear all
NCT01806064 2020-10-19

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Terminated
173 enrolled 17 charts
Genitourinary

Carcinoma, Renal Cell

NCT02664961 2019-07-23

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Tracon Pharmaceuticals Inc.

Phase 2 Terminated
3 enrolled 11 charts
Gynecologic

Choriocarcinoma, Trophoblastic Tumor, Placental Site, Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡